Home

Zomedica Corp. Common Shares (ZOM)

0.0973
+0.00 (0.00%)
NYSE · Last Trade: Dec 15th, 5:40 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.0973
Open-
Bid0.0970
Ask0.0984
Day's RangeN/A - N/A
52 Week Range0.0943 - 0.1580
Volume0
Market Cap95.35M
PE Ratio (TTM)-0.9730
EPS (TTM)-0.1
Dividend & YieldN/A (N/A)
1 Month Average Volume-

Chart

About Zomedica Corp. Common Shares (ZOM)

Zomedica Pharmaceuticals Corp is a veterinary-focused healthcare company dedicated to developing innovative diagnostic and therapeutic products for companion animals, particularly dogs and cats. The company aims to enhance the quality of care for pets and improve their health outcomes through its advanced diagnostic tools. Zomedica's flagship product line includes diagnostics that help veterinarians detect and monitor various health conditions, empowering them to make informed decisions regarding treatment options. With a commitment to improving animal health, Zomedica seeks to support veterinary practices with effective solutions that ultimately lead to better pet care. Read More

News & Press Releases

Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv
The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated movie Merv now available on Prime Video
Via ACCESS Newswire · December 11, 2025
Zomedica Expands TRUFORMA(R) Diagnostic Menu with Launch of Equine Progesterone Assay
Newest assay expands TRUFORMA market opportunity by building on endocrinology foundation to address reproductive health in the equine segment
Via ACCESS Newswire · December 4, 2025
Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review
November session to provide strategic context for Zomedica's product platforms featured in the previous Fourth Friday at Four Webinars
Via ACCESS Newswire · November 11, 2025
Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential
Certification enhances global market readiness, reinforces quality systems, and supports Zomedica's long-term growth strategy
Via ACCESS Newswire · November 6, 2025
Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth
Zomedica posts highest quarterly revenue ever and record year-over-year revenue for 19th straight quarter!
Via ACCESS Newswire · November 4, 2025
Zomedica Corp. Announces Transition to OTCQB Venture Market
Zomedica's ticker symbol will change to ZOMDF
Via ACCESS Newswire · March 4, 2025
Zomedica Announces Launch of the Assisi Loop Lounge(R), Scientifically Backed tPEMF(TM) Therapy for Pets
Combining peer-reviewed science, superior comfort, and thoughtful design, the Assisi Loop Lounge expands Zomedica's evidence-based therapeutic portfolio and reinforces Assisi's leadership in targeted tPEMF innovation
Via ACCESS Newswire · October 23, 2025
Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union
Expanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in the multi-billion-dollar global veterinary diagnostics and therapeutic device markets
Via ACCESS Newswire · October 14, 2025
Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October "Fourth Friday at Four" Webinar
Live session on October 24th will showcase how the VETGuardian Monitor enhances patient care, improves workflow efficiency, and expands global market opportunities
Via ACCESS Newswire · October 9, 2025
Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay
First and only in-clinic multiplexed Cobalamin & Folate assay now validated for feline patients
Via ACCESS Newswire · September 23, 2025
Zomedica Expands TRUVIEW(R) and TRUFORMA(R) Intellectual Property Portfolio with Four Newly Issued U.S. Patents
Intellectual property portfolio now includes 228 Patents and 153 Trademarks providing robust protection for the Company's product platforms in the rapidly growing multi-billion dollar veterinary diagnostics market
Via ACCESS Newswire · September 18, 2025
Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW(R) Digital Cytology Microscope - Transforming Veterinary Imaging
Cutting-Edge Digital Microscopy System Featured in Monthly Series Showcasing Innovation in Veterinary Care
Via ACCESS Newswire · September 12, 2025
Zomedica and UXR Announce Expanded Distribution Agreement in Canada
Agreement strengthens Canadian veterinarians' access to Zomedica's advanced therapeutic and monitoring solutions
Via ACCESS Newswire · September 10, 2025
Zomedica Strengthens UK Market Position with Strategic Distribution Agreement for High-Growth Veterinary Innovation Portfolio
Strategic partnership with Pioneer Veterinary Products Limited expands Zomedica's presence in the UK veterinary market through distribution of its leading point-of-care solutions
Via ACCESS Newswire · September 3, 2025
Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices
New agreement brings innovative shock wave, tPEMF therapy, monitoring, and bleeding control solutions to more than 2,200 member clinics nationwide
Via ACCESS Newswire · August 19, 2025
Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL(R) Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine
Revolutionary Plant-Based Technology Gains Momentum as a Game-Changer in Wound Management
Via ACCESS Newswire · August 12, 2025
Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth
Zomedica posts record year-over-year revenue for 18th straight quarter!
Via ACCESS Newswire · August 6, 2025
Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the Assisi(R) Line - Advancing Drug-Free Healing for Pets
Breakthrough tPEMF™ Technology Showcased in Monthly Series Exploring Innovation in Veterinary Care
Via ACCESS Newswire · July 16, 2025
Zomedica Announces Strategic PulseVet(R) Shock Wave Partnership with World Equestrian Center – Ocala
Elevating Equine Health and Show Experience with Leading Shock Wave Therapy
Via ACCESS Newswire · July 10, 2025
Zomedica Announces Issuance of Additional Patent for its TRUVIEW(R) Microscope
Intellectual Property Portfolio grows to 221 Patents and 140 Trademarks
Via ACCESS Newswire · June 24, 2025
Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform(R) - Revolutionizing In-Clinic Diagnostics
Next-Generation Diagnostic Platform Takes Center Stage in Monthly Series Showcasing Innovation in Veterinary Care
Via ACCESS Newswire · June 19, 2025
Zomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample Dilution
The TRUFORMA Platform now has the widest dynamic range (without manual dilution) available either at the Point of Care or from a Reference Lab
Via ACCESS Newswire · May 21, 2025
Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations
Engaging Sessions to Highlight Game-Changing Technologies, Expert Insights, and Growth Opportunities in Animal Health Featuring Zomedica Products
Via ACCESS Newswire · May 19, 2025
Zomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave Therapy
Innovative Registry Harnesses Shock Wave Therapy to Advance Non-Drug Equine Asthma Treatment and Drive Evidence-Based Veterinary Care
Via ACCESS Newswire · May 13, 2025
Earnings Scheduled For March 13, 2025benzinga.com
Via Benzinga · March 13, 2025